ATLANTA, July 7, 2026
Nyra Medical, Inc. has announced the enrollment of the first patient in its ENHANCE Early Feasibility Study (EFS), marking a major milestone in the clinical development of the investigational CARLEN™ System, an innovative transcatheter mitral valve repair platform designed to treat patients with functional mitral regurgitation (FMR). The study expands Nyra Medical’s global clinical program into the United States and Brazil following encouraging First-in-Human clinical experience, reinforcing the company’s commitment to developing next-generation structural heart technologies that address significant unmet clinical needs. Functional mitral regurgitation is one of the most challenging cardiovascular diseases to manage because many patients are not suitable candidates for conventional surgical procedures or currently available transcatheter therapies. The investigational CARLEN System introduces a differentiated treatment approach by restoring native mitral valve leaflet coaptation without relying on sutures, tethers, or permanent alteration of the valve anatomy. This unique design aims to preserve the heart’s natural valve motion while maintaining future treatment options for physicians and patients. The first patient enrollment represents another important step toward generating the clinical evidence required for future regulatory submissions and eventual commercialization.
ENHANCE Study Expands Global Clinical Development
The ENHANCE Early Feasibility Study is a prospective, multicenter, single-arm clinical investigation evaluating the safety, procedural performance, feasibility, and long-term clinical outcomes of the investigational CARLEN™ System in patients diagnosed with symptomatic moderate-to-severe or severe functional mitral regurgitation. Patients enrolled in the study will be followed for five years, allowing investigators to assess both procedural success and long-term device performance.
Leading structural heart centers across the United States and Brazil are participating in the study, with InCor – University of São Paulo Hospital becoming the first enrolling site in Brazil and UC Davis Health serving as the first participating center in the United States. Company executives emphasized that the study reflects years of engineering innovation, rigorous clinical planning, and close collaboration with internationally recognized cardiovascular specialists. The successful initiation of ENHANCE strengthens Nyra Medical’s global evidence-generation strategy while supporting future regulatory milestones for its novel transcatheter therapy.
Innovative Technology Targets Significant Unmet Need
Advertisement
Unlike traditional transcatheter edge-to-edge repair systems, the investigational CARLEN™ System has been specifically engineered to augment the native mitral leaflet, restore physiological valve function, and preserve normal leaflet motion without permanently modifying valve anatomy. This innovative design may provide physicians with greater flexibility when treating patients whose anatomy or ventricular disease limits the effectiveness of currently available repair technologies. Cardiovascular experts participating in the study highlighted the platform’s potential to expand treatment options for patients living with functional mitral regurgitation, a condition associated with worsening heart failure, reduced quality of life, and increased mortality if left untreated.
Nyra Medical leadership stated that the successful enrollment of the first patient validates the company’s long-term strategy of combining engineering excellence with clinical collaboration to develop transformative structural heart solutions. The company also acknowledged the contributions of leading physicians whose expertise helped shape the evolution of the CARLEN platform throughout its early clinical development. As enrollment continues across additional international centers, Nyra Medical expects the ENHANCE study to provide critical clinical evidence supporting future regulatory review and broader commercial adoption. The successful launch of the ENHANCE Early Feasibility Study represents a significant advancement in structural heart innovation, demonstrating Nyra Medical’s continued commitment to improving minimally invasive cardiovascular therapies through clinically driven research and next-generation medical device technology.
Source: Nyra Medical press release
